Evaluating the effectiveness of biological treatments in rheumatoid arthritis patients
Persistence of Biological Treatment and Inhibitors of Jak Kinases in Habitual Clinical Practice in Patients With Rheumatoid Arthritis. Influence of the Comorbidities.
This study is testing how well different biological treatments work for people with rheumatoid arthritis over a long period of time.
Quick facts
| Study type | Observational |
|---|---|
| Enrollment | 540 (estimated) |
| Ages | 18 Years and up |
| Sex | All |
| Sponsor | Fundación Pública Andaluza para la gestión de la Investigación en Sevilla Academic / other |
| Drugs / interventions | Rituximab |
| Locations | 1 site (Seville) |
| Trial ID | NCT05062421 on ClinicalTrials.gov |
What this trial studies
This observational study focuses on patients with rheumatoid arthritis who are treated with targeted synthetic and biologic disease-modifying drugs. The study aims to assess the persistence and effectiveness of various medications, including JAK inhibitors and monoclonal antibodies, over a follow-up period of up to 84 months. Patients will be monitored through regular consultations to evaluate their health outcomes and treatment responses. The goal is to gather data on how these treatments impact the long-term health of patients.
Who should consider this trial
Good fit: Ideal candidates for this study are adults aged 18 and older diagnosed with rheumatoid arthritis who have received at least one dose of the study drugs.
Not a fit: Patients who do not have sufficient baseline and follow-up data or those with incomplete medical records may not benefit from this study.
Why it matters
Potential benefit: If successful, this study could provide valuable insights into the long-term effectiveness of various treatments for rheumatoid arthritis, potentially improving patient care.
How similar studies have performed: Other studies have shown success in evaluating the effectiveness of similar treatments in rheumatoid arthritis, suggesting that this approach is supported by existing research.
Eligibility criteria
Show full inclusion / exclusion criteria
Inclusion Criteria: * Patients aged ≥18 years. * With a diagnosis of Adult Rheumatoid Arthritis according to the 2010 ACR / EULAR criteria. * Who have received at least one of the doses of the study drugs. * In follow-up in the consultations of the UGC of Rheumatology of the HUVM. * With at least two complete evaluations (baseline and final) of clinical variables. Exclusion Criteria: * Patients where the medical records lack sufficient baseline and final variables to perform the analysis. * Patients in whom more than 50% of the variables to be collected are missing in the data collection.
Where this trial is running
Seville
- Hospital Universitario Virgen macarena — Seville, Spain (Recruiting)
Study contacts
- Principal investigator: Blanca Estela Hernández Cruz — Hospital Universitario Virgen Macarena
- Study coordinator: Blanca Estela Hernández Cruz
- Email: blancahcruz@gmail.com
- Phone: 955008000
How to participate
- Review the eligibility criteria above with your treating physician.
- Visit the official trial page on ClinicalTrials.gov for the most current contact information and recruitment status.
- Contact the listed study coordinator or principal investigator to request pre-screening. Pre-screening is free and never obligates you to enroll.